Cocrystal Pharma Inc (COCP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cocrystal Pharma Inc (COCP) has a cash flow conversion efficiency ratio of -0.569x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.34 Million) by net assets ($4.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see COCP market cap for the company's overall valuation and market capitalisation.
Cocrystal Pharma Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Cocrystal Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cocrystal Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cocrystal Pharma Inc ranked by their cash flow conversion efficiency. Explore Cocrystal Pharma Inc (COCP) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polygiene AB
ST:POLYG
|
0.000x |
|
Bharat Road Network Limited
NSE:BRNL
|
-0.109x |
|
Megapolitan Developments Tbk
JK:EMDE
|
-0.004x |
|
BTC Health Ltd
AU:BTC
|
-0.023x |
|
Tips Films Limited
NSE:TIPSFILMS
|
0.372x |
|
Kritika Wires Limited
NSE:KRITIKA
|
0.010x |
|
Tae Won Mulsan
KO:001420
|
0.007x |
|
INNO-GENE SA ZY -10
F:WQ3
|
0.003x |
Annual Cash Flow Conversion Efficiency for Cocrystal Pharma Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Cocrystal Pharma Inc from 2007 to 2025. View Cocrystal Pharma Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.33 Million | $-8.19 Million | -1.294x | +25.25% |
| 2024-12-31 | $9.52 Million | $-16.48 Million | -1.731x | -211.42% |
| 2023-12-31 | $26.38 Million | $-14.67 Million | -0.556x | -2.61% |
| 2022-12-31 | $39.57 Million | $-21.43 Million | -0.542x | -230.30% |
| 2021-12-31 | $77.55 Million | $-12.72 Million | -0.164x | +12.40% |
| 2020-12-31 | $52.51 Million | $-9.83 Million | -0.187x | -207.94% |
| 2019-12-31 | $25.71 Million | $-1.56 Million | -0.061x | +50.94% |
| 2018-12-31 | $66.89 Million | $-8.29 Million | -0.124x | -89.24% |
| 2017-12-31 | $105.40 Million | $-6.90 Million | -0.065x | +54.27% |
| 2016-12-31 | $102.32 Million | $-14.65 Million | -0.143x | -132.67% |
| 2015-12-31 | $167.59 Million | $-10.32 Million | -0.062x | +93.19% |
| 2014-12-31 | $6.65 Million | $-6.01 Million | -0.903x | -219.17% |
| 2013-12-31 | $-6.03 Million | $-4.57 Million | 0.758x | +84.47% |
| 2012-12-31 | $-3.58 Million | $-1.47 Million | 0.411x | +170.34% |
| 2011-12-31 | $-2.77 Million | $-420.95K | 0.152x | +105.45% |
| 2010-12-31 | $6.93K | $-19.34K | -2.791x | -506.59% |
| 2009-12-31 | $54.54K | $-25.10K | -0.460x | -30.68% |
| 2008-12-31 | $95.34K | $-33.58K | -0.352x | -51.65% |
| 2007-12-31 | $147.13K | $-34.17K | -0.232x | -- |
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more